In an exciting development for the tech and video production industries, OneTake A.I. has successfully secured $1,000,000 in funding towards its mission of revolutionizing the way content creators and businesses approach video editing. OneTake A.I. offers an innovative autonomous video editing solution that transforms up to 10 hours of raw footage into a polished, professional-grade final product鈥攁ll with a single click. This game-changing technology not only simplifies the editing process but also enhances the quality of output by incorporating titles, transitions, and animations seamlessly. With this new round of funding, OneTake A.I. aims to enhance its platform's capabilities, invest in cutting-edge machine learning algorithms, and expand its outreach to a broader audience of content creators, marketers, and businesses seeking to elevate their video marketing strategies. The ability to quickly produce captivating video content is integral in today's fast-paced digital landscape, helping companies attract more leads, drive sales, and ultimately, reclaim valuable time to focus on what matters most. With this financial boost, OneTake A.I. is poised to not only enhance its technology but to position itself as a leader in the autonomous editing space, empowering all creators to easily produce high-quality videos that resonate with their audiences. As the demand for engaging video content continues to grow, OneTake A.I. stands at the forefront of this evolution, ready to meet the needs of businesses seeking a competitive edge in their marketing efforts.
Revolutionizing Video Editing: OneTake AI Secures $1 Million in Seed Funding
Recently funded 路 $1.0M SeedTechnology/Software
Get the full OneTake AI company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Xentra
From cyber security, through to safeguarding and compliance, we provide digital security solutions perfectly designed to suit any requirement. Our team of experts will help you assess, select and implement the right solutions for your organisation; setting you up for success and helping you deliver against key objectives. We pride ourselves on understanding the digital security landscape, thoroughly evaluating available technologies and building long-term partnerships with our customers. We don鈥檛 believe in quick fixes. Whether you require a point solution to tackle a single requirement, or would benefit from a complete managed service, our solutions are built to stand the test of time. Since 2020, we鈥檝e been helping organisations such as Leeds United Football Club, Thomas鈥檚 London Day Schools, Setfords, JT Atkinson and Northern Estate Agencies Group, manage and optimise their overall digital security. Along the way, we have set the standard for what a customer-first approach to digital security looks like, and how to measure success.
$3.5M Series a
today
Estrigenix Therapeutics, Inc.
Estrigenix Therapeutics, Inc. is a privately held pharmaceutical company developing the next generation of innovative therapies for improving the mental health of menopausal women. Menopause is associated with cognitive dysfunction, increased mood and anxiety disorders, and an elevated risk of Alzheimer鈥檚 disease, yet standard estrogen therapies are associated with increased risks of cancer, heart disease, and stroke. Our mission is to develop novel drugs that mitigate the adverse effects of menopause on mental health and enable women to live healthier and happier lives. The drug development program at Estrigenix focuses on selectively activating specific estrogen receptor proteins that promote memory formation, improve mood, and reduce anxiety. We believe that targeting these receptors will provide the cognitive and mood-enhancing benefits of estrogens without the harmful side effects of standard estrogen therapies. Our lead compound, EGX-358, is a potent and selective agonist of the estrogen receptor beta protein, which enhances memory formation in a mouse model of menopause. Current work is expanding the use of this compound to other indications, including depression, anxiety, and hot flashes.
Other recent Seed rounds
Companies that recently closed a Seed round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | Estrigenix Therapeutics, Inc. United States | Seed | $2.0M | today |
| 2 |  Investre Luxembourg | Seed | $2.6M | today |
